Anubha Anti-Ageing Medicine


A fascinating discovery in genetic testing is the ability to detect genes which disturb the safe/normal
detoxification of prescribed drugs (Pharmacogenetics). With the knowledge of specific polymorphisms
of drug detoxifying genes, personalised prescriptions of specific medications can be offered as well
which drugs to avoid, as severe reactions could result.

This is Pharmacogenomics. There is an increasing use of pharmacogenomics in medicine. For example,
patients with a Factor V Leiden  or Prothrombin Factor II mutation need to avoid HRT and periods of
immobilisation otherwise there is a higher risk of venous thrombosis. In cancer management,
Non-small cell lung cancer patients with a gene mutation of Epidermal Growth Factor Receptor (EGFR)
are eligible for gefitinib treatment as a first-line therapy which provides better disease free survival, and
quality of life with less side-effects than standard chemotherapy with carboplatin and paclitaxel.

Already seminal research articles are appearing in the scientific press, which alludes to the benefit of
knowing which drugs to use for which people. The advantages to patients are enormous as the risk of
iatrogenic (doctor induced) morbidity and mortality is diminished profoundly.

A study from the USA in 2003 reported that more people died of iatrogenic disease (doctor induced
illness) then from heart disease or cancer.

Go to Glossary of Terms
Go back to Anubha's Programs of Investigation
Go back to Anubha's Home Page